Full Breakdown
Johnson & Johnson Ordered to Pay $40 Million in Talc Lawsuit
12/16/2025, 3:45:26 AM
Jury Verdict and Implications
A California jury has ordered Johnson & Johnson (J&J) to pay $40 million to two women, Monica Kent and Deborah Schultz, who claimed that the company's talc-based baby powder caused their ovarian cancer. The Los Angeles Superior Court awarded $18 million to Kent and $22 million to Schultz and her husband after determining that J&J had failed to adequately warn consumers about the potential dangers of its products. Both women testified that they had used J&J's baby powder for approximately 40 years, with Kent diagnosed in 2014 and Schultz in 2018.
Background of the Case
The trial, which lasted four weeks, included testimony from former FDA Commissioner David Kessler, who asserted that J&J was aware of the potential link between asbestos in talc and cancer since the 1970s but concealed this information. J&J has consistently denied these claims, maintaining that its talc products are safe and free from asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch-based alternative.
Ongoing Legal Challenges
This verdict marks a significant moment in J&J's ongoing legal battles, with over 67,000 lawsuits currently pending against the company related to talc products. The company has faced a mixed record in previous trials, with some verdicts reaching as high as $4.69 billion. In October 2025, a jury awarded $966 million to the family of a woman who died from mesothelioma, further complicating J&J's legal landscape. The company has attempted to resolve these lawsuits through bankruptcy proceedings, but federal courts have rejected these attempts, stating that J&J did not demonstrate sufficient financial distress.
Official Statements & Responses
In response to the verdict, Erik Haas, J&J's worldwide vice president of litigation, announced that the company plans to appeal the decision, expressing confidence in prevailing against what he termed "aberrant adverse verdicts." J&J's legal team argued that the connection between talc and cancer is not supported by major health authorities, asserting that the plaintiffs lacked sufficient evidence to establish causation.
Criticism & Opposition
Critics argue that J&J's long history of litigation and the substantial verdicts against the company highlight a failure in corporate responsibility. The plaintiffs' attorneys emphasized that J&J had a duty to inform consumers of the risks associated with its talc products, a sentiment echoed by public health advocates who classify talc as a "possible carcinogen" under certain conditions.
What's Next
As J&J prepares to appeal the recent verdict, the company faces a series of upcoming trials related to talc products, with expectations of at least ten trials through the first half of 2026. The outcomes of these cases will likely continue to shape public perception and legal precedents regarding corporate accountability in the consumer goods industry.
